1. Background
Hepatitis B (HB) is one of the viruses that attack the liver and can cause both acute and chronic hepatitis, representing a serious public health problem. It is estimated that more than 2 billion people (1/3 of the global population) have been infected with the hepatitis B virus (HBV) worldwide, of whom 360 million are chronic HBV carriers (from 4% to 6% of the global population) (1). The possibility of chronic HBV infection depends upon the age at which a person is infected. After HBV exposure, the risk of developing chronic hepatitis B (CHB) infection is less than 5% in adults and adolescents; however, for children < 5 years of age and newborns, the risks are as high as 25 ~ 30% and 80 ~ 90%, respectively (2, 3). Furthermore, from 15% to 40% of HBV chronic carriers are expected to progressively develop cirrhosis, hepatocellular carcinoma (HCC) and end-stage liver failure (4).
China used to be an area with a high rate of HBV infection and one of the main transmission routes was mother-to-child transmission. Since implementing the Expanded Program on Immunization (EPI) in 1992 (this program recommends that all newborns receive three doses of recombination HB vaccine: 5 μg at 0, 1 and 6 months), the prevalence of hepatitis B surface antigen (HBsAg) in China has been reduced from 9.8% in 1992 to 7.2% in 2006 (5). Although vaccination is effective in preventing vertical transmission, there are still a number of children infected each year. It was reported that approximately 10% of the children whose mothers were positive for HBsAg and hepatitis B e antigen (HBeAg) did not achieve the protection level and ultimately developed CHB (6).HBV infection is generally attributed to immunological factors, viral factors, environmental factors and host genetic factors. Recently, several genome-wide association studies (GWAS) have reported that genetic variants in the human leukocyte antigen (HLA) are associated with prolonged HBV infection or HBV clearance in adults (7). Kamatani et al. (8) and Mbarek et al. (9) demonstrated that single nucleotide polymorphisms (SNPs) at HLA-DPA1, HLA-DPB1, HLA-DQB1 and HLA-DQB2 were strongly associated with chronic HBV infection in Japanese and Korean populations. The association was also proved by Hu et al. (10) and Guo et al. (11) in the Chinese population. However, whether genetic variants in HLA influence the outcome of HBV infection and breakthrough in children still remains unknown. In this study, we aimed to use a case-control study to identify and confirm whether those reported SNPs in adults are related to HBV infection in children.
2. Objectives
The aim of this study was to explore the association between SNPs at HLA loci and HBV infection and breakthrough in children.
3. Methods
3.1. Study Subjects
During October 2013 and May 2015, a total of 627 Han Chinese children were consecutively recruited from the hospital of Chongqing medical university and health center for women and children in Chongqing. Of these children, 274 were HBsAg positive (cases) and 353 were HBsAg negative (controls). Diseased children were included if they were aged from 6 months to 12 years, were HBsAg positive for over 6 months regardless of their alanine aminotransferase (ALT) levels, HBV DNA levels or HBeAg status. Control children were included if they were from the same hospital, were HBsAg negative and had normal serum ALT levels. Subjects with other liver diseases or autoimmune diseases were excluded. Blood samples were collected from the study children and their mothers for further use. Data regarding physical examinations, delivery modes, feeding patterns and HBV vaccination in the study children were obtained from their medical records or questionnaire interviews. The research was conducted according to the guidelines of the world medical association declaration of Helsinki. Written informed consent was obtained from all the subjects in accordance with the study protocol approved by the ethics committee of Chongqing medical university.
3.2. Laboratory Testing
HBV markers (HBsAg, HBsAb, HBeAg, HBeAb and HBcAb) in the subjects and their mothers were tested by enzyme-linked immunosorbent assay (ELISA). Diagnostic kits were purchased from the Shanghai Kehua bioengineering technology company, limited (Shanghai, China). Human genomic DNA samples were extracted from venous blood samples using a BioTeke DP6101 kit (BioTeke corporation, Beijing, China) according to the manufacturer’s instructions. The DNA concentration was measured by Nanodrop2000c spectrophotometer (Thermo Scientific, DE). The eluted DNA was stored at -80°C for further use.
3.3. SNP Genotyping
Seven SNPs (rs3077 at HLA-DPA1; rs9277535, rs2281388 and rs3135021 at HLA-DPB1; rs9366816 at HLA-DPB2; rs2856718 at HLA-DQB1; and rs7453920 at HLA-DQB2) were selected in total. Genotyping was performed according to the mass array time-of-flight mass spectrometer (Sequenom company, USA). Polymerase chain reaction (PCR) and extension primers were designed using MassARRAY assay design 3.1 software (Sequenom company, USA). The genotyping procedures were performed according to the manufacturer’s iPLEX application guide (Sequenom company, USA). The PCR amplification conditions included an initial precycle incubation of 94°C for 15 minutes, followed by 45 cycles of denaturation at 94°C for 20 seconds, annealing at 56°C for 30seconds, and extension at 72°C for 60seconds. All the genotyping reactions were performed in 384-well plates. Each plate included four randomly selected duplicates and six negative controls using double distilled water. The average concordance rate for the genotypes was 99.5%.
3.4. Statistical Analysis
Statistical analysis was performed with the statistical package for the social sciences (version 17.0, SPSS Inc., Chicago, IL, USA) on a computer. Descriptive statistics (mean, standard deviation and percentage) were conducted to reflect the background characteristics of the participants. Categorical and continuous values were compared by the χ2 test, which was also used for the genetic model analysis. Fisher’s exact test was applied when the χ2 test could not be used in certain circumstances. Each component of the model was as follows: allele A versus allele B, A as the major allele, B as the minor allele, dominant model (AB + BB versus AA), recessive model (BB versus AB + AA), codominant model (AA versus AB versus BB), and overdominant model (AA + BB versus AB). The Hardy-Weinberg equilibrium was used to test for the deviation of genotype distribution. Logistic regression was performed for the association between variants in the seven selected SNPs and HBV infection by computing odds ratios (ORs) and 95% confidence intervals (CIs). A P value < 0.05 was defined as statistically significant.
4. Results
4.1. General Characteristics of the Subjects
Baseline characteristics of the study subjects are provided in Table 1. A total of 627 subjects (361 children were males) were recruited in this study, including 274 patients (90 children were born to HBsAg-positive mothers) and 353 controls (132 children were born to HBsAg-positive mothers). The characteristics of sex, HBIG and HBV vaccination, delivery mode and mother’s HBV infection status showed significant differences between the two groups (P < 0.05).
Table 1. General Characteristics of HBV-Infected Children and Control Childrena
| Variables | Cases, n = 274 | Controls, n = 353 | P Value |
|---|---|---|---|
| Sex, No. (%) | 0.004 | ||
| Male | 180 (65.7) | 181 (51.4) | |
| Female | 94 (34.3) | 171 (48.6) | |
| Age, month , mean ± SD | 73.9 ± 48.3 | 30.3 ± 18.0 | 0.000 |
| HBV vaccination, No. (%) | 0.000 | ||
| Yes | 101 (87.1) | 353 (100) | |
| No | 15 (12.9) | 0 (0) | |
| HBIG, No. (%) | 0.010 | ||
| Yes | 47 (52.2) | 132 (37.4) | |
| No | 43 (47.8) | 221 (62.6) | |
| Delivery mode, No. (%) | 0.001 | ||
| Spontaneous delivery | 103 (54.5) | 48 (36.4) | |
| Cesarean delivery | 86 (45.5) | 84 (63.6) | |
| Feeding patterns, No. (%) | 0.474 | ||
| Breast feeding | 63 (33.7) | 37 (28.0) | |
| Mixed feeding | 21 (11.2) | 19 (14.4) | |
| Artificial feeding | 103 (55.1) | 76 (57.6) | |
| HBsAg (+) mothers, No. (%) | 0.000 | ||
| HBeAg (+) | 44 (48.9) | 37 (28.0) | |
| HBeAg (-) | 9 (10.0) | 61 (46.2) | |
| Others | 37 (41.1) | 34 (25.8) |
Abbreviation: HBIG, hepatitis B immunoglobulin; SD, Standard deviation.
aP < 0.05 was considered significant.
4.2. Relation of the SNPs and HBV Infection Risk in Children
The genotype distributions of SNPs were in accordance with the Hardy-Weinberg equilibrium in both groups. As shown in Table 2, SNPs rs3077 GG genotype in HLA-DPA1 and rs9277535 GG genotype in HLA-DPB1 were significantly associated with HBV infection after adjustment by sex, age, HBV vaccination, HBIG treatment, maternal HBV infection status, delivery mode and feeding patterns (OR = 1.584, 95% CI = 1.012-2.480, P = 0.004; OR = 2.199, 95% CI = 1.389 - 3.480, P = 0.001; respectively). The risk alleles of G were found in both SNPs, with ORs of 1.309 (95% CI 1.046 to 1.639) and 1.411 (95% CI 1.125 to 1.771), respectively.
Table 2. Genotype Distribution in HLA Loci and Their Association with HBV Infection in Children
| Gene | SNP | Genotype | Cases, % | Controls, % | Crude OR (95% CI) | P Value | Adjusted OR (95% CI)a | P Valuea |
|---|---|---|---|---|---|---|---|---|
| HLA-DPA1 | rs3077 | |||||||
| AA | 132 (48.2) | 186 (53.6) | 1 | 1 | ||||
| GA | 0 (0) | 9 (2.6) | - | 0.999 | 0.999 | |||
| GG | 142 (51.8) | 152 (43.8) | 1.316 (0.956 - 1.812) | 0.092 | 1.584(1.012 - 2.480) | 0.004 | ||
| A | 264 (48.2) | 381 (54.9) | 1 | |||||
| G | 284 (51.8) | 313 (45.1) | 1.309 (1.046 - 1.639) | 0.019 | ||||
| HLA-DPB1 | rs2281388 | |||||||
| GG | 82 (29.9) | 122 (35.2) | 1 | 1 | ||||
| GA | 150 (54.7) | 159 (45.8) | 1.404 (0.981 - 2.008) | 0.063 | 1.478(0.885 - 2.468) | 0.135 | ||
| AA | 42 (15.3) | 66 (19.0) | 0.947 (0.587 - 1.526) | 0.822 | 1.188(0.621 - 2.272) | 0.602 | ||
| G | 314 (57.3) | 403 (58.1) | 1 | |||||
| A | 234 (42.7) | 291 (41.9) | 1.032 (0.823 - 1.295) | 0.785 | ||||
| HLA-DPB1 | rs3135021 | |||||||
| GG | 167 (60.9) | 227 (65.6) | 1 | 1 | ||||
| GA | 97 (35.4) | 104 (30.1) | 1.268 (0.901 - 1.783) | 0.173 | 0.893(0.546 - 1.462) | 0.654 | ||
| AA | 10 (3.6) | 15 (4.3) | 0.906 (0.397-2.067) | 0.815 | 1.026(0.333 - 3.166) | 0.964 | ||
| G | 431 (78.6) | 558 (80.6) | 1 | |||||
| A | 117 (21.4) | 134 (19.4) | 1.130 (0.856-1.493) | 0.387 | ||||
| HLA-DPB1 | rs9277535 | |||||||
| AA | 149 (54.4) | 212 (60.1) | 1 | 1 | ||||
| GA | 1 (0.4) | 20 (5.7) | 0.071 (0.009-0.536) | 0.010 | 0.108(0.014 - 0.834) | 0.033 | ||
| GG | 124 (45.3) | 121 (34.3) | 1.458 (1.052 - 2.021) | 0.024 | 2.199(1.389-3.480) | 0.001 | ||
| A | 299 (54.6) | 444 (62.9) | 1 | |||||
| G | 249 (45.4) | 262 (37.1) | 1.411 (1.125 - 1.771) | 0.003 | ||||
| HLA-DPB2 | rs9366816 | |||||||
| TT | 60 (21.9) | 94 (27.1) | 1 | 1 | ||||
| TC | 161 (58.8) | 172 (49.6) | 1.466 (0.994 - 2.163) | 0.054 | 1.480(0.851 - 2.575) | 0.165 | ||
| CC | 53 (19.3) | 81 (23.3) | 1.025 (0.638 - 1.647) | 0.918 | 1.077(0.551 - 2.107) | 0.828 | ||
| T | 281 (51.3) | 360 (51.9) | 1 | |||||
| C | 267 (48.7) | 334 (48.1) | 1.024 (0.819 - 1.281) | 0.835 | ||||
| HLA-DQB1 | rs2856718 | |||||||
| TT | 177 (64.6) | 231 (66.6) | 1 | 1 | ||||
| TC | 60 (21.9) | 66 (19.0) | 1.186 (0.795 - 1.771) | 0.403 | 1.135(0.655 - 1.966) | 0.653 | ||
| CC | 37 (13.5) | 50 (14.4) | 0.966 (0.605 - 1.542) | 0.884 | 0.898(0.463 - 1.741) | 0.751 | ||
| T | 414 (75.5) | 528 (76.1) | 1 | |||||
| C | 134 (24.5) | 166 (23.9) | 1.030 (0.793 - 1.337) | 0.827 | ||||
| HLA-DQB2 | rs7453920 | |||||||
| GG | 232 (84.7) | 293 (83.7) | 1 | 1 | ||||
| GA | 39 (14.2) | 53 (15.1) | 0.929 (0.594 - 1.454) | 0.784 | 0.776(0.408 - 1.474) | 0.438 | ||
| AA | 3 (1.1) | 4 (1.1) | 0.947 (0.210 - 4.274) | 0.944 | 0.443(0.045 - 4.364) | 0.485 | ||
| G | 503 (91.8) | 639 (91.3) | 1 | |||||
| A | 45 (8.2) | 61 (8.7) | 0.937 (0.627 - 1.402) | 0.752 |
Abbreviation: CI, confidence interval; OR, odds ratio; SNP, single nucleotide polymorphism.
aThe P values and OR (95% CI) were calculated from logistic regression analyses adjusting for sex, age, HBV vaccination, HBIG treatment, maternal HBV infection status, delivery mode and feeding patterns.
We conducted a genetic model analysis among the seven SNPs and the results are presented in Table 3. Four genetic models were applied in this study. The dominant model: the risk genotype GG was identified in both rs3077 and rs9277535, with ORs of 1.724 (95% CI 1.105 to 2.691) and 2.484 (95% CI 1.577 to 3.913), respectively. The overdominant model: the genotype GA in rs9277535 was found to be a protective factor for HBV infection in children (OR = 0.076, 95% CI 0.010 - 0.583). In addition, the rs2281388 GA and rs9366816 TC genotypes were correlated with HBV susceptibility, respectively (rs2281388, OR = 1.422, 95% CI 1.032-1.961; rs9366816, OR = 1.444, 95% CI 1.045 - 1.994). Finally, the codominant model: the rs9277535 AA genotype and rs3077 AA genotype were still found to be significantly different between cases and controls (P = 0.044, P = 0.001). Only the rs9277535 genotype was observed to be significantly different in recessive model analysis (OR = 1.752, 95% CI 1.123 - 2.735).
Table 3. Association Between SNPs and HBV Infection in Children Using Genetic Models
| Gene | SNP | Model | Genotype | Crude OR (95% CI) | P Value | Adjusted OR (95% CI)a | P Valuea |
|---|---|---|---|---|---|---|---|
| HLA-DPA1 | rs3077 | Dominant | GA+AA/GG | 1.380 (1.004 - 1.897) | 0.047 | 1.724 (1.105 - 2.691) | 0.016 |
| Recessive | AA/GA + GG | 1.243 (0.905 - 1.707) | 0.179 | 1.429(0.918 - 2.224) | 0.114 | ||
| Overdominant | GG + AA/GA | - | 0.999 | - | 0.999 | ||
| Codominant | GG/GA | - | 0.999 | - | 0.999 | ||
| GG/AA | 0.760 (0.552 - 1.046) | 0.092 | 1.584 (1.012 - 2.480) | 0.044 | |||
| HLA-DPB1 | rs2281388 | Dominant | GA + AA/GG | 0.788 (0.561 - 1.106) | 0.168 | 0.719 (0.442 - 1.170) | 0.184 |
| Recessive | AA/GA + GG | 1.297 (0.849 - 1.983) | 0.228 | 1.074 (0.614 - 1.878) | 0.802 | ||
| Overdominant | GG + AA/GA | 1.430 (1.041 - 1.966) | 0.027 | 1.422 (1.032 - 1.961) | 0.032 | ||
| Codominant | GG/GA | 1.404 (0.981 - 2.008) | 0.063 | 1.481 (0.881 - 2.492) | 0.139 | ||
| GG/AA | 0.947 (0.587 - 1.526) | 0.822 | 1.172 (0.614 - 2.237) | 0.630 | |||
| HLA-DPB1 | rs3135021 | Dominant | GA + AA/GG | 0.818 (0.589 - 1.137) | 0.231 | 1.101 (0.687 - 1.764) | 0.689 |
| Recessive | AA/GA + GG | 1.196 (0.529 - 2.706) | 0.666 | 0.940 (0.308 - 2.870) | 0.914 | ||
| Overdominant | GG + AA/GA | 1.275 (0.910 - 1.788) | 0.158 | 0.892 (0.548 - 1.453) | 0.646 | ||
| Codominant | GG/GA | 1.268 (0.901 - 1.783) | 0.173 | 0.892 (0.546 - 1.459) | 0.650 | ||
| GG/AA | 0.906 (0.397 - 2.067) | 0.815 | 1.043 (0.338 - 3.220) | 0.942 | |||
| HLA-DPB1 | rs9277535 | Dominant | GA + AA/GG | 1.585 (1.147 - 2.191) | 0.005 | 2.484 (1.577 - 3.913) | 0.000 |
| Recessive | AA/GA + GG | 1.261 (0.917 - 1.736) | 0.154 | 1.752 (1.123 - 2.735) | 0.013 | ||
| Overdominant | GG + AA/GA | 0.061 (0.008 - 0.457) | 0.000 | 0.076 (0.010 - 0.583) | 0.013 | ||
| Codominant | GG/GA | 0.049 (0.006 - 0.369) | 0.003 | 0.053 (0.007 - 0.421) | 0.005 | ||
| GG/AA | 0.686 (0.495 - 0.951) | 0.024 | 0.454 (0.287 - 0.720) | 0.001 | |||
| HLA-DPB2 | rs9366816 | Dominant | TC + CC/TT | 0.755 (0.520 - 1.094) | 0.137 | 0.740 (0.435 - 1.259) | 0.267 |
| Recessive | CC/TC + TT | 1.270 (0.860 - 1.875) | 0.229 | 1.221 (0.711 - 2.099) | 0.469 | ||
| Overdominant | TT + CC/TC | 1.450 (1.053 - 1.996) | 0.023 | 1.444 (1.045 - 1.994) | 0.026 | ||
| Codominant | TT/TC | 1.466 (0.994 - 2.163) | 0.054 | 1.464 (0.839 - 2.553) | 0.180 | ||
| TT/CC | 1.025 (0.638 - 1.647) | 0.918 | 1.078 (0.552 - 2.106) | 0.827 | |||
| HLA-DQB1 | rs2856718 | Dominant | TC + CC/TT | 0.916 (0.657 - 1.279) | 0.607 | 0.967 (0.608 - 1.536) | 0.885 |
| Recessive | CC/TC + TT | 1.078 (0.682 - 1.705) | 0.747 | 1.148 (0.601 - 2.194) | 0.676 | ||
| Overdominant | TT + CC/TC | 1.194 (0.806 - 1.767) | 0.376 | 1.156 (0.675 - 1.980) | 0.598 | ||
| Codominant | TT/TC | 1.186 (0.795 - 1.771) | 0.403 | 1.135 (0.655 - 1.967) | 0.651 | ||
| TT/CC | 0.966 (0.605 - 1.542) | 0.884 | 0.912 (0.474 - 1.752) | 0.781 | |||
| HLA-DQB2 | rs7453920 | Dominant | GA + AA/GG | 1.075 (0.696 - 1.659) | 0.745 | 1.341 (0.718 - 2.505) | 0.358 |
| Recessive | AA/GA + GG | 1.044 (0.232 - 4.705) | 0.955 | 2.163 (0.220 - 21.260) | 0.508 | ||
| Overdominant | GG + AA/GA | 0.930 (0.594 - 1.455) | 0.751 | 0.785 0.414 - 1.491) | 0.460 | ||
| Codominant | GG/GA | 0.929 (0.594 - 1.454) | 0.784 | 0.776 (0.409 - 1.474) | 0.439 | ||
| GG/AA | 0.947 (0.210 - 4.274) | 0.944 | 0.467 (0.048 - 4.575) | 0.513 |
Abbeviation: CI, confidence interval; OR, odds ratio; SNP, single nucleotide polymorphism.
aThe P values and OR (95% CI) were calculated from logistic regression analyses adjusting for sex, age, HBV vaccination, HBIG treatment, maternal HBV infection status, delivery mode and feeding patterns.
4.3. Relation of the SNPs and HBV Breakthrough Risk in Children
We further explored the association of those SNPs at HLA loci and HBV breakthrough infection in children who were born to HBsAg-positive mothers. As shown in Table 4, after adjustment by age, sex, delivery mode and feeding patterns, genotype GA in rs9277535 in HLA-DPB1 was also identified to be significantly associated with HBV breakthrough infection in the children whose mothers were positive for HBsAg (OR = 0.098, 95% CI 0.013-0.770, P = 0.027).
Table 4. Association Between SNPs and Risk of HBV Breakthrough Infection in Children Born to HBsAg (+) Mothers
| Gene | SNP | Genotype | Cases, % | Controls, % | Crude OR (95% CI) | P Value | Adjusted OR (95% CI)a | P Valuea |
|---|---|---|---|---|---|---|---|---|
| HLA-DPA1 | rs3077 | |||||||
| AA | 42 (46.7) | 64 (49.6) | 1 | 1 | ||||
| GA | 0 (0) | 9 (7.0) | - | 0.025 | 0.999 | |||
| GG | 48 (53.3) | 56 (43.4) | 1.306 (0.755 - 2.259) | 0.339 | 1.305(0.750 - 2.271) | 0.346 | ||
| A | 84 (46.7) | 137 (53.1) | 1 | |||||
| G | 96 (53.3) | 121 (46.9) | 1.294 (0.884 - 1.895) | 0.185 | ||||
| HLA-DPB1 | rs2281388 | |||||||
| GG | 26 (28.9) | 39 (30.2) | 1 | 1 | ||||
| GA | 49 (54.4) | 59 (45.7) | 1.246 (0.667 - 2.326) | 0.490 | 1.340(0.710 - 2.526) | 0.366 | ||
| AA | 15 (16.7) | 31 (24.0) | 0.726 (0.329 - 1.601) | 0.427 | 0.808(0.361 - 1.805) | 0.602 | ||
| G | 101 (56.1) | 137 (53.1) | 1 | |||||
| A | 79 (43.9) | 121 (46.9) | 0.886 (0.604 - 1.298) | 0.534 | ||||
| HLA-DPB1 | rs3135021 | |||||||
| GG | 61 (67.8) | 87 (68.0) | 1 | 1 | ||||
| GA | 25 (27.8) | 38 (29.7) | 0.938 (0.514 - 1.712) | 0.836 | 0.902(0.491 - 1.659) | 0.741 | ||
| AA | 4 (4.4) | 3 (2.3) | 1.902 (0.411 - 8.802) | 0.411 | 1.588(0.337 - 7.479) | 0.558 | ||
| G | 147 (81.7) | 212 (82.8) | 1 | |||||
| A | 33 (18.3) | 44 (17.2) | 1.082 (0.657 - 1.780) | 0.757 | ||||
| HLA-DPB1 | rs9277535 | |||||||
| AA | 46 (51.1) | 72 (54.5) | 1 | 1 | ||||
| GA | 1 (1.1) | 19 (14.4) | 0.082 (0.011 - 0.636) | 0.017 | 0.098(0.013 - 0.770) | 0.027 | ||
| GG | 43 (47.8) | 41 (31.1) | 1.642 (0.932 - 2.890) | 0.086 | 1.677(0.949 - 2.966) | 0.075 | ||
| A | 93 (51.7) | 163 (61.7) | 1 | |||||
| G | 87 (48.3) | 101 (38.3) | 1.510 (1.029 - 2.215) | 0.035 | ||||
| HLA-DPB2 | rs9366816 | |||||||
| TT | 19 (21.9) | 30 (23.3) | 1 | 1 | ||||
| TC | 55 (61.1) | 68 (52.7) | 1.277 (0.650 - 2.510) | 0.478 | 1.373(0.691 - 2.728) | 0.365 | ||
| CC | 16 (17.8) | 31 (24.0) | 0.815 (0.354 - 1.875) | 0.630 | 0.863(0.371 - 2.005) | 0.732 | ||
| T | 93 (51.7) | 128 (49.6) | 1 | |||||
| C | 87 (48.3) | 130 (50.4) | 0.921 (0.629 - 1.348) | 0.672 | ||||
| HLA-DQB1 | rs2856718 | |||||||
| TT | 55 (61.1) | 87 (67.4) | 1 | 1 | ||||
| TC | 23 (25.6) | 24 (18.6) | 1.516 (0.780 - 2.945) | 0.220 | 1.151(0.773 - 2.970) | 0.227 | ||
| CC | 12 (13.3) | 18 (14.0) | 1.055 (0.472 - 2.358) | 0.897 | 0.946(0.417 - 2.144) | 0.894 | ||
| T | 133 (73.9) | 198 (76.7) | 1 | |||||
| C | 47 (26.1) | 60 (23.3) | 1.166 (0.751 - 1.812) | 0.494 | ||||
| HLA-DQB2 | rs7453920 | |||||||
| GG | 75 (83.3) | 110 (84.0) | 1 | 1 | ||||
| GA | 14 (15.6) | 19 (14.5) | 1.081 (0.510 - 2.288) | 0.839 | 0.984(0.459 - 2.108) | 0.966 | ||
| AA | 1 (1.1) | 2 (1.5) | 0.733 (0.065 - 8.233) | 0.802 | 0.559(0.049 - 6.349) | 0.639 | ||
| G | 164 (91.1) | 239 (91.2) | 1 | |||||
| A | 16 (8.9) | 23 (8.8) | 1.014 (0.520 - 1.978) | 0.968 |
Abbreviation: CI, confidence interval; SNP, single nucleotide polymorphism; OR, odds ratio.
aThe P values and OR (95% CI) were calculated from logistic regression analyses adjusting for sex , age, HBV vaccination, HBIG treatment, delivery mode and feeding patterns.
5. Discussion
In this study, we investigated polymorphisms in HLA-DP and HLA-DQ genes for HBV infection susceptibility in children. Our study firstly pointed out that four SNPs (HLA-DPA1 rs3077, HLA-DPB1 rs9277535, rs2281388 and HLA-DPB2 rs9366816) were significantly associated with HBV infection in children. Accumulating evidence has demonstrated that HLA-DP/DQ variants were associated with HBV infection in adults. Mbarek et al. reported that genetic variants in HLA-DQ loci (rs2856718 and rs7453920) were strongly related to HBV infection in the Japanese population (9), which was also confirmed in the Korean and Chinese Han populations (10, 12). However, neither of the two currently hot SNPs showed significant signals in our study in children. This is possibly explained by the fact that children’s immune systems have not yet fully developed in comparison to those of adults, thus causing different immune mechanisms to address HBV infection.
A number of previous studies, including GWAS, found that SNPs (rs3077 and rs9277535) in the HLA-DP gene were highly associated with chronic HBV infection in Asians (8, 11, 13, 14). In our present study, there was a statistical difference in both allele G and genotype GG levels of the two SNPs when comparing patients with HBV infection and healthy children. This finding suggests that the rs3077 and rs9277535 major G alleles are risk factors for HBV infection, which is consistent with the previous studies. O’Brien et al. found that rs3077 and rs9277535 were also strongly associated with the decreased mRNA expression of HLA-DPA1 and HLA-DPB1 respectively, indicating that lower expression of HLA-DPA1 and HLA-DPB1 is a factor for increased risk of chronic HBV infection (15), which shows that the expression of these genes is important for the control of HBV replication. However, whether the variants in HLA-DP are related to liver cirrhosis or HCC development remains to be seen. Liao et al. found that HLA-DP polymorphisms (rs3077 or rs9277535) were not associated with HCC development, but were related to HBV susceptibility and HBV natural clearance (13). Hu et al. demonstrated that a variant at rs9277534 in HLA-DPB1 could influence both the spontaneous clearance of HBV infection and progression from asymptomatic HBV carriers to HBV-related liver cirrhosis in the Southwest Han Chinese population (16).
Additionally, through genetic model analysis, our study found that rs9366816 (TT + CC versus TC) near HLA-DPB2 showed significant association with HBV infection in children. This finding was consistent with a previous study in male Han Taiwanese, which showed that rs9366816 is an independent contributor to HBV susceptibility (17). Zhang et al. reported that another SNP rs2281388 (GG + AA versus GA) in HLA-DPB1 was statistically related to HBV infection in genotype B of HBV-infected subjects (18).
A new finding identified in this study was that rs9277535 variants are still significantly related to HBV infection in children who were born to HBsAg-positive mothers. The children in our study were all born later than 2002 and were older than 6 months when China began the immunization program offering free HB vaccine to all neonates. Both routine HB vaccines and HBIG are recommended at birth for infants born to HBsAg-positive mothers. Mother-to-child transmission of HBV remains one of the main transmission routes in China and is also the cause of a rate of 5 - 10% immunoprophylaxis failure (19). High levels of maternal viral load and HBeAg titer might induce the vaccination failure (20, 21). Escape mutants in the “a” determinant region and S gene of HBV might be associated with vaccination failure in some infants (22, 23). Such mutants could potentially escape neutralizing HBsAb and infect vaccinated persons. Recently, a study in Taiwan showed that immunized children who were born to genotype C mothers might have a higher rate of breakthrough infection than those who were born to genotype B mothers (24). The difference in the results mentioned above is possibly explained by the fact that the effect of host genetic variants in HBV infection was not taken into consideration. Family clustering analysis and twin studies showed that host genetic factors could explain 63 - 85% of vaccine responses to hepatitis B virus (25). Yan et al. demonstrated that host genetic factors played a dominant role in determining HBV vaccination responses in infants (91%), as compared with perinatal environmental factors (26). In addition, Komatsu et al. found that although HLA-DPA1 (rs3077) variants did not show statistical associations with early HBeAg seroconversion, they might increase the possibility of achieving early spontaneous HBeAg seroconversion in children (27). In our study, we identified that HLA-DPB1 rs9277535 was related to HBV breakthrough infection in children who were born to HBsAg-positive mothers. These genetic variants might be a useful reminder when developing a new HB genomic vaccine to more adequately prevent the spread of HBV.
In conclusion, the genetic variants of four SNPs (rs3077, rs9277535, rs2281388 and rs9366816) in HLA-DPA1 and HLA-DPB1 loci have significant associations with HBV infection and breakthrough in children. This study provides insight into HBV infection in children and is valuable for the targeted management of, and control strategies for, this disease.
